United States - English - NLM (National Library of Medicine)

fresenius kabi norge as - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - zyvox is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. zyvox is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [ see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [ s

United States - English - NLM (National Library of Medicine)

fresenius kabi norge as - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - zyvox is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. zyvox is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [ see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [ s

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - zyvox is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see clinical studies (14) ]. zyvox is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [ see clinical studies (14) ]. zyvox is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or streptococcus agalactiae . zyvox has not been studied in the treatment of decubitus ulcers [ see clin

United States - English - NLM (National Library of Medicine)

fresenius kabi norge as - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - zyvox is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. zyvox is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [ see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [ s

United States - English - NLM (National Library of Medicine)

fresenius kabi norge as - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - zyvox is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. zyvox is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [ see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [ s

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; ethylcellulose; silicon dioxide; povidone; microcrystalline cellulose; diethyl phthalate; purified talc - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - linezolid (form iii) - film coated tablet - 600 milligram - linezolid - antibacterials for systemic use; other antibacterials - linezolid is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; maize starch; sodium starch glycollate type a; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; hyprolose; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.